Valneva SE (NASDAQ:VALN - Get Free Report)'s stock price dropped 11.2% during mid-day trading on Friday . The company traded as low as $6.87 and last traded at $6.92. Approximately 79,836 shares were traded during trading, an increase of 30% from the average daily volume of 61,567 shares. The stock had previously closed at $7.79.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Valneva in a research note on Friday, January 31st.
Get Our Latest Analysis on Valneva
Valneva Price Performance
The firm's fifty day simple moving average is $5.03 and its 200-day simple moving average is $5.64. The firm has a market capitalization of $595.64 million, a PE ratio of -56.38 and a beta of 1.98. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.
Hedge Funds Weigh In On Valneva
Several hedge funds and other institutional investors have recently added to or reduced their stakes in VALN. ABC Arbitrage SA bought a new position in shares of Valneva during the fourth quarter valued at $84,000. AlphaCentric Advisors LLC lifted its stake in Valneva by 33.7% during the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock valued at $717,000 after acquiring an additional 29,748 shares during the period. Finally, Wells Fargo & Company MN boosted its holdings in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after acquiring an additional 30,859 shares during the last quarter. 11.39% of the stock is owned by institutional investors.
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Read More
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
